K-V Pharmaceutical Company was a U.S.‐based specialty pharmaceutical firm focused on the acquisition, development, manufacturing and commercialization of prescription drugs. Founded in 1999 and headquartered in St. Louis, Missouri, the company built its portfolio by securing licensing agreements for under‐promoted pharmaceutical products and pursuing targeted FDA approvals to establish niche market franchises.
The company primarily served the United States market, operating manufacturing and distribution facilities in St. Louis and Horsham, Pennsylvania. K-V’s therapeutic focus included women’s health, neuroscience, critical care and dermatology. Its flagship product, Makena (hydroxyprogesterone caproate injection), received FDA approval in February 2011 to reduce the risk of recurrent preterm birth in women with a history of spontaneous preterm delivery.
K-V’s business strategy centered on identifying mature or off‐patent drugs with limited commercial reach, negotiating exclusive U.S. marketing rights, and applying patent and regulatory strategies to extend product longevity. This approach allowed the company to concentrate resources on specialty indications rather than compete in broad‐spectrum mass‐market categories.
In December 2013, K-V Pharmaceutical filed for Chapter 11 bankruptcy protection and in September 2014 agreed to be acquired by AMAG Pharmaceuticals. Following the transaction, K-V’s marketed assets, including Makena, were integrated into AMAG’s portfolio, bringing K-V’s independent operations to a close.
AI Generated. May Contain Errors.
